Patterns of bone density evaluation in a community population treated with aromatase inhibitors

Breast Cancer Research and Treatment

Volumn 134, Issue 3, 2012, Pages 1305-1313

  Ligibel, Jennifer A ^a   James O'Malley, A ^b   Fisher, Maxine ^c   Daniel, Gregory W ^d   Winer, Eric P ^a   Keating, Nancy L ^b,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HEALTHCORE INC   (United States)

^d BROOKINGS INSTITUTION   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aromatase inhibitor; Bone density; Breast cancer

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; ARTICLE; BONE DENSITY; BONE EXAMINATION; BREAST CANCER; CANCER CHEMOTHERAPY; COMMUNITY ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; EDUCATIONAL STATUS; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; MIDDLE AGED; TIME FACTORS;

EID: 84868197329     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2151-0     Document Type: Article

References (26)

1. Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057
2. National Comprehensive Cancer Network NCC (2005) Breast Cancer Clinical Practice Guidelines. In Edition 2005.v1
3. Gralow JR, Biermann JS, Farooki A et al (2009) NCCN Task Force Report: bone health in cancer care. J Natl Compr Canc Netw 7(Suppl 3):S1-S32 quiz S33-35
4. Theriault RL, Biermann JS, Brown E et al (2006) NCCN Task Force Report: bone health and cancer care. J Natl Compr Canc Netw 4(Suppl 2):S1-S20 quiz S21-22
5. Hadji P, Body JJ, Aapro MS et al (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19:1407-1416
6. Hadji P, Aapro M, Body J et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22:2546
7. Neuner JM, Binkley N, Sparapani RA et al (2006) Bone density testing in older women and its association with patient age. J Am Geriatr Soc 54:485-489
8. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383
10. Lau YT, Ahmed NN (2012) Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy 32:67-79
11. Santen RJ (2011) Clinical review: effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab 96:308-319
12. Earle CC, Burstein HJ, Winer EP, Weeks JC (2003) Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol 21:1447-1451
13. Snyder CF, Frick KD, Kantsiper ME et al (2009) Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol 27:1054-1061
14. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359:2131-2139
15. Thurlmann B, Keshaviah A, Mouridsen H, Mauriac L (2005) BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol 23:511
16. Goss P, Ingle J, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802
17. Jakesz R, Jonat W, Gnant M, Mittlboeck M (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from ABCSG trial 8 and the ARNO 95 trial. Lancet 366:455-462
18. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group (2005) Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
19. Llombart A, Frassoldati A, Paija O et al (2012) Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer:12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12:40-48
20. Eidtmann H, De Boer R, Bundred N et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole:36-month results of the ZO-FAST Study. Ann Oncol 21:2188-2194
21. Bundred NJ, Campbell ID, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 112:1001-1010
22. Brufsky AM, Harker WG, Beck JT et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118:1192-1201
23. Iwase H (2008) Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 15:278-290
24. Bilezikian JP (2009) Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 122:S14-S21
25. Edwards BJ, Raisch DW, Shankaran V et al (2011) Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res 17:560-568
26. Hershman DL, Shao T, Kushi LH et al (2010) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537